This module aims to provide an overview of current treatment options of familial hypercholesterolaemia (FH), challenges in the management of FH and the role of evolocumab in reducing low-density lipoprotein cholesterol (LDL-C) in FH patients.
This Continuous Medical Education (CME) is supported by Amgen Biopharmaceuticals Malaysia Sdn Bhd.
You must be a member to access this content.
To become a member, please register here.
If you're already a member, please sign in to access.